All News
Filter News
Found 809,008 articles
-
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
6/1/2023
Vaccinex, Inc. announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 to 10:25 am Eastern Time in New York City, NY and invites investors to participate in one-on-one meetings that same day.
-
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
6/1/2023
LYNPARZA ® (olaparib) plus abiraterone approved in the US for the treatment of BRCA -mutated metastatic castration-resistant prostate cancer.
-
Zymeworks Announces Participation in Upcoming June 2023 Investor Conferences
6/1/2023
Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced that management will participate in the following upcoming investor conferences.
-
CoRegen Inc. Announces Publication of Preclinical Research Demonstrating Treatment with Modified Tregs Eliminates Tumors and Prevents Recurrence Without Side Effects
6/1/2023
CoRegen announced today the publication of research, titled, “Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion,” in the peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS).
-
4D Molecular Therapeutics to Participate in Upcoming June 2023 Investor Conferences
6/1/2023
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced it will participate in the following upcoming investor conferences.
-
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
6/1/2023
Bayer and Cedilla Therapeutics today announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.
-
The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023
6/1/2023
The Max Foundation announced the launch of its Max Access Solutions program to deliver access to treatment for HR+/HER2- advanced breast cancer patients in collaboration with leading oncologists in low and middle-income countries.
-
Exact Sciences Earns 2023 Great Place to Work® Certification™
6/1/2023
Exact Sciences Corp. announced that the company has been certified as a 2023 Great Place To Work® for the fifth consecutive year.
-
Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023
6/1/2023
Eyenovia, Inc. announced that the company will be delivering a presentation at the annual OCTANE Ophthalmology Tech Forum 2023, which is being held June 8-9 in Newport Beach, CA.
-
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
6/1/2023
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam.
-
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead
6/1/2023
IO Biotech announced that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company’s lead cancer vaccine candidate.
-
Gain Therapeutics to Present at the 2023 Jefferies Healthcare Conference
6/1/2023
Gain Therapeutics, Inc. announced that Matthias Alder, Chief Executive Officer, will present at the Jefferies Healthcare Conference, taking place June 7-9 in New York, NY.
-
Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights to Intellectual Property From Georgetown University for Azeliragon as a Potential Treatment of Cancer-Related Cognitive Decline
6/1/2023
Cantex Pharmaceuticals, Inc. announced that it has obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent or alleviate cancer-treatment related cognitive decline.
-
Freudenberg Medical Utilizes VR Training in Catheter Manufacturing
6/1/2023
Freudenberg Medical, a global CDMO for finished medical devices, components, and minimally invasive solutions, has implemented virtual reality training for employees working in catheter production at operations in Ireland and the United States.
-
Pharming announces sale of priority review voucher
6/1/2023
Pharming Group N.V. announces that it has entered into a definitive agreement with Novartis Pharma A.G. to sell its Rare Pediatric Disease Priority Review Voucher to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.
-
Immunocore to present at upcoming June 2023 investor conferences
6/1/2023
Immunocore Holdings Plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, announced that management will present at the following investor conferences in June:
-
Miromatrix Announces CEO Jeff Ross, Ph.D. will Expand His Role by Resuming Leadership of R&D
6/1/2023
Miromatrix Medical Inc. announced that Miromatrix and John Barry have mutually agreed to end his employment as Vice President of Research and Development effective on or around June 13, 2023, and that Jeff Ross, Ph.D., Chief Executive Officer, will assume leadership responsibilities for the R&D organization.
-
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down
6/1/2023
Navidea Biopharmaceuticals, Inc. announced Jill Bieker Stefanelli, Ph.D. has joined the Company’s Board of Directors, adding deep experience developing and advancing precision medicine products in line with Navidea’s stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market.
-
REALM IDx Launches REALM Pharma Services to Improve Drug Development and Research
6/1/2023
REALM IDx announced the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners.
-
Compass Therapeutics to Participate in Upcoming June 2023 Investor Events
6/1/2023
Compass Therapeutics, Inc. announced that the Company will participate in the following investor events during the month of June 2023.